This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Insider Trading Alert - DVA, ACN And BIIB Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, April 2, 2014, 123 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $278.57 to $71,423,275.14.

Highlighted Stocks Traded by Insiders:

DaVita HealthCare Partners (DVA) - FREE Research Report

Mildenberger Laura who is Chief People Officer at DaVita HealthCare Partners sold 598 shares at $69.22 on April 2, 2014. Following this transaction, the Chief People Officer owned 5,438 shares meaning that the stake was reduced by 9.91% with the 598-share transaction.

Staffieri Michael David who is COO, Kidney Care at DaVita HealthCare Partners sold 2,867 shares at $69.15 on April 2, 2014. Following this transaction, the COO, Kidney Care owned 2,633 shares meaning that the stake was reduced by 52.13% with the 2,867-share transaction.

The shares most recently traded at $69.01, down $0.14, or 0.2% since the insider transaction. Historical insider transactions for DaVita HealthCare Partners go as follows:

  • 4-Week # shares sold: 16,489
  • 12-Week # shares sold: 26,489
  • 24-Week # shares sold: 26,489

The average volume for DaVita HealthCare Partners has been 1.5 million shares per day over the past 30 days. DaVita HealthCare Partners has a market cap of $14.8 billion and is part of the health care sector and health services industry. Shares are up 9.01% year-to-date as of the close of trading on Wednesday.

DaVita HealthCare Partners Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease. It operates kidney dialysis centers and provides related lab services primarily in outpatient dialysis centers and in contracted hospitals. The company has a P/E ratio of 24.0. Currently there are 9 analysts that rate DaVita HealthCare Partners a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DVA - FREE

TheStreet Quant Ratings rates DaVita HealthCare Partners as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in stock price during the past year, growth in earnings per share, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full DaVita HealthCare Partners Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
Submit an article to us!

Markets

DOW 17,884.62 +79.82 0.45%
S&P 500 2,070.12 -0.53 -0.03%
NASDAQ 4,766.1190 +0.7390 0.02%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs